Showing posts from May, 2024Show all
Media Update: Sanofi update on Zantac litigation health-issue

Media Update: Sanofi update on Zantac litigation

Nitesh sinha May 31, 2024

https://ift.tt/cwIu3S4 Sanofi update on Zantac litigation from Sanofi - Aventis Groupe https://ift.tt/GUVLPMr via IFTTT

Read more
Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan health-issue

Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan

Nitesh sinha May 31, 2024

https://ift.tt/plbZu6V Sanofi launches 2024 global Employee Stock Purchase Plan from Sanofi - Aventis Groupe https://ift.tt/oOHRctD via IFTTT

Read more
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation health-issue

Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation

Nitesh sinha May 31, 2024

https://ift.tt/z3UdqOj   from Sanofi - Aventis Groupe https://ift.tt/CXtZpzg via IFTTT

Read more
Press Release: Sanofi completes acquisition of Inhibrx, Inc. health-issue

Press Release: Sanofi completes acquisition of Inhibrx, Inc.

Nitesh sinha May 30, 2024

https://ift.tt/ByYXWro Sanofi completes acquisition of Inhibrx, Inc. from Sanofi - Aventis Groupe https://ift.tt/HgKkCef via IFTTT

Read more
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma health-issue

Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma

Nitesh sinha May 26, 2024

https://ift.tt/TOZCYia   from Sanofi - Aventis Groupe https://ift.tt/FeV2OIA via IFTTT

Read more
Media Update: New results from rilzabrutinib phase 2 study show potential to be first advanced oral treatment for moderate-to-severe asthma health-issue

Media Update: New results from rilzabrutinib phase 2 study show potential to be first advanced oral treatment for moderate-to-severe asthma

Nitesh sinha May 22, 2024

https://ift.tt/BvtVAcM New results from rilzabrutinib phase 2 study show potential to be first advanced oral treatment for moderate-to-severe asthma …

Read more
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration health-issue

Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

Nitesh sinha May 21, 2024

https://ift.tt/BV6btO0 Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration from Sanofi - Aventis Groupe https://ift.tt/UqAQn…

Read more
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM health-issue

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM

Nitesh sinha May 20, 2024

https://ift.tt/ePwYfTG   from Sanofi - Aventis Groupe https://ift.tt/nrzsOaQ via IFTTT

Read more
Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty health-issue

Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty

Nitesh sinha May 13, 2024

https://ift.tt/R6E9xkI   from Sanofi - Aventis Groupe https://ift.tt/LZWGMmV via IFTTT

Read more
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines health-issue

Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

Nitesh sinha May 09, 2024

https://ift.tt/LjfJ1c4    Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-CO…

Read more
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations health-issue

Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations

Nitesh sinha May 01, 2024

https://ift.tt/CiS5r43 Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations from Sanofi - Aven…

Read more